Should a patient with new‑onset multiple sclerosis receive weekly Solu‑Medrol (methylprednisolone) infusions?

Weekly Solu-Medrol Infusions for New-Onset MS: Not Recommended

Weekly methylprednisolone infusions are not the standard of care for new-onset multiple sclerosis and should not be used as routine maintenance therapy. The evidence clearly supports high-dose methylprednisolone only for acute relapse treatment, not as scheduled weekly prophylaxis.

Standard Treatment Protocol for New-Onset MS

For Acute Relapses Only

The FDA-approved regimen for MS relapses is 160 mg methylprednisolone daily for 1 week, followed by 64 mg every other day for 1 month 1. This is specifically for treating acute exacerbations, not for scheduled weekly administration.

Alternative acute relapse protocols include:

• 1000 mg IV methylprednisolone daily for 3-5 days 2, 3
• This accelerates recovery from relapses but does not influence long-term disability or prevent future relapses 3

Monthly Pulsed Therapy: Limited Evidence

The only evidence for regularly scheduled corticosteroids in MS involves monthly (not weekly) administration:

• Monthly methylprednisolone (1g IV once per month for 12 months) as add-on therapy to interferon beta or glatiramer acetate reduced annualized relapse rates by 62-69% in small studies 4, 5
• However, these studies had significant limitations: high dropout rates (26%), small sample sizes, and were only studied as add-on therapy to disease-modifying treatments, not as monotherapy 5

Why Weekly Infusions Are Not Appropriate

1. No evidence base: There are no studies supporting weekly methylprednisolone infusions for MS
2. Wrong frequency: The studied interval is monthly, not weekly 4, 5
3. Significant adverse effects: More frequent dosing increases risks of:
   • Sleep disturbance
   • Neuropsychiatric symptoms 5
   • Bone mineral density loss (though not seen at monthly intervals) 5
   • HPA axis suppression 1
   • Increased infection risk 1

Recommended Approach for New-Onset MS

Start a disease-modifying therapy (DMT) immediately rather than relying on corticosteroids:

• First-line DMTs include interferon beta, glatiramer acetate, teriflunomide, dimethyl fumarate, or higher-efficacy agents depending on disease severity 6
• Reserve methylprednisolone for acute relapses only using the standard 3-5 day high-dose protocol 3, 7, 8

If Considering Pulsed Corticosteroids

Only consider monthly (not weekly) pulsed methylprednisolone if:

• Patient is already on a DMT (interferon beta or glatiramer acetate)
• Breakthrough relapses continue despite DMT
• Use 1g IV methylprednisolone once monthly for up to 12 months 4

Critical Pitfalls to Avoid

• Do not use weekly corticosteroids as monotherapy for MS—this has no evidence and exposes patients to unnecessary toxicity
• Do not substitute scheduled corticosteroids for proper DMT initiation—this delays appropriate disease-modifying treatment
• Do not continue pulsed corticosteroids beyond 12 months without reassessing the treatment plan 4

The evidence is clear: methylprednisolone has a role in MS for acute relapse treatment (3-5 days) or potentially as monthly add-on therapy to DMTs, but weekly infusions have no supporting data and represent inappropriate use of corticosteroids.